Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phas
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigatorSite activation comes several months ahead of schedule, significantly accelerating Starton’s clinical program timelinePARAMUS, N.J.--(BUSINESS WIRE)--Starton Therapeutics Inc. (“Starton” or “the Company”...
Source: pharmiweb.com